Can ginkgo biloba alter Alzheimer's blood signs?
NCT ID NCT07579689
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a daily 240 mg dose of Ginkgo biloba extract can change certain blood markers linked to Alzheimer's disease in people with mild cognitive impairment. Over 6 months, 120 participants will be randomly assigned to receive either Ginkgo biloba or a placebo. The main goal is to see if the supplement affects levels of p-tau217 and other proteins in the blood, which may indicate changes in disease activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ginkgo biloba extract (240 mg daily)
What this could lead to
If it works, this could show that Ginkgo biloba affects Alzheimer's-related blood markers, pointing toward a possible way to slow disease progression.
What could go wrong
This is a small, early-phase trial focused on biomarkers, not clinical outcomes. Ginkgo biloba has not been proven to treat Alzheimer's, and results may not lead to a clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••